PLRZ.US Polyrizon Ltd. Ordinary Shares

Healthcare Biotechnology USA Stocks
11.05 USD
Close of Nov 15, 2026
2.88 18.20
Market cap
USD 26.8M
P/E
-
P/B
1.10x
ROE
-17.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PLRZ.US undervalued?

Graham number

The Graham number of Polyrizon Ltd. Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Polyrizon Ltd. Ordinary Shares fundamental analysis

No fundamental analysis for Polyrizon Ltd. Ordinary Shares yet.

Polyrizon Ltd. Ordinary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Polyrizon Ltd. Ordinary Shares

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incor…

Full company profile